Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PIGUP1 is annotated as a processed pseudogene in humans, as shown in Ensembl and HGNC[3]. Pseudogenes are generally nonfunctional DNA segments resembling protein-coding genes but that have lost coding potential due to mutations, deletions, or truncations. There is no evidence in authoritative genomic databases, recent literature, or curated gene resources of any protein product, biological function, or disease association for PIGUP1. It is not an established drug target, nor does it have therapeutic, diagnostic, or biomarker relevance. The naming can sometimes cause confusion with other “PIG” gene family members that are involved in GPI anchor biosynthesis, which are functional genes with therapeutic significance. However, PIGUP1 itself is specifically indicated as a pseudogene and should not be considered a molecular target[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphatidylinositol glycan anchor biosynthesis class U pseudogene 1 (PIGUP1).